Skip to content

Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.

Deborah C. Mash, J K Staley, Michael H. Baumann, Richard B Rothman, W L Hearn

Life Sciences 1995 DOI: 10.1016/0024-3205(95)00273-9 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Experimental study Peer reviewed
Interventions Ibogaine 12-hydroxyibogamine
Topics Ibogaine Serotonin
Citations 108
Key findings 12-hydroxyibogamine, a metabolite of ibogaine, elevates extracellular serotonin by binding with high affinity to the serotonin transporter, while neither ibogaine nor its metabolite increase dopamine levels in the nucleus accumbens.

Abstract

Ibogaine is a hallucinogenic indole with putative efficacy for the treatment of cocaine, stimulant and opiate abuse. The purported efficacy of ibogaine following single dose administrations has led to the suggestion that a long-acting metabolite of ibogaine may explain in part how the drug reduces craving for psychostimulants and opiates. We report here that 12-hydroxyibogamine, a primary metabolite of ibogaine, displays high affinity for the 5-HT transporter and elevates extracellular 5-HT. In radioligand binding assays, 12-hydroxyibogamine was 50-fold more potent at displacing radioligand binding at the 5-HT transporter than at the DA transporter. Ibogaine and 12-hydroxyibogamine were equipotent at the dopamine transporter. In vivo microdialysis was used to evaluate the acute actions of ibogaine and 12-hydroxyibogamine on the levels of DA and 5-HT. Administration of 12-hydroxyibogamine produced a marked dose-related elevation of extracellular 5-HT. Ibogaine and 12-hydroxyibogamine failed to elevate DA levels in the nucleus accumbens over the dose range tested. The elevation in synaptic levels of 5-HT by 12-hydroxyibogamine may heighten mood and attenuate drug craving. The effects of the active metabolite on 5-HT transmission may account in part for the potential of ibogaine to interrupt drug-seeking behavior in humans.